Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

Abstract Background Weekly paclitaxel + ramucirumab (wPTX + RAM) therapy is recommended as the standard second-line chemotherapy regimen for unresectable advanced/recurrent gastric cancer (GC) or esophagogastric junction cancer. Recent subgroup analysis of the RAINBOW trial revealed a higher frequen...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Katsuhiko Nara, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, Hiroshi Suzuki
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: BMC 2023-10-01
Sarja:BMC Cancer
Aiheet:
Weekly paclitaxel + ramucirumab
Febrile neutropenia
Oxaliplatin
Total bilirubin
Gastric/Esophagogastric cancer
Linkit:https://doi.org/10.1186/s12885-023-11469-y

Internet

https://doi.org/10.1186/s12885-023-11469-y

Samankaltaisia teoksia